Posts

Kelun's sac-TMT scores win in first-line PD-L1-negative NSCLC population missing from Merck's KEYTRUDA phase 3 program

on

FDA delays camizestrant breast cancer drug decision after ODAC vote against benefit-risk profile

on

Remepy Reports Strong Clinical Phase IIa Results for Hybridopa, a First‑in‑Class Hybrid Drug for Parkinson’s Disease

on

AbbVie’s Skyrizi yields to UCB’s Bimzelx in psoriatic arthritis head‑to‑head trial

on

Pfizer's Elrexfio Meets Phase III Primary Endpoint in Multiple Myeloma, Positioning Drug for Earlier-Line Use

on

Novartis Presents Rhapsido (Remibrutinib) Data at AAAAI 2026, Highlighting Potential Beyond CSU

on

Novo Nordisk's Next-Gen Obesity Drug Outperforms Wegovy in Phase III Blood Sugar Control

on

Amgen Ends Autoimmune Alliance with Kyowa Kirin for Rocatinlimab Amid Safety and Efficacy Concerns

on

Roche's CT-388 Obesity Drug Achieves 22.5% Weight Loss in Phase II, Advances to Phase III

on

METiS BioTech Announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial

on

Priovant Announces Successful Phase III Results for Brepocitinib in Dermatomyositis (VALOR Study)

on

AstraZeneca's Saphnelo Succeeds in Phase III as Self-Injectable Lupus Treatment

on

Regeneron Prepares U.S. Submission for Garetosmab After Breakthrough Phase III Result in Ultra-Rare FOP

on

LB Pharmaceuticals Upsizes IPO to $285M, Marks First Major Biotech Listing in Months

on

Phase III Study: Perioperative Padcev & Keytruda Combo Significantly Improves Survival in Bladder Cancer

on

Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies

on

Regenxbio Reports Consistent One-Year Benefit for DMD Gene Therapy RGX-202

on

GSK Acquires Phase III-Ready Liver Drug Efimosfermin for Up to $2B to Enter MASH Arena

on